Advances in targeted therapies IV
F C Breedveld, J R Kalden, and J S Smolen
Ann Rheum Dis 2002; 61 (Supplement 2
): 1. doi:10.1136/ard.61.suppl_2.ii1
[Extract]
[Full text]
[PDF]
[Request Permissions]
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
D E Furst, F C Breedveld, J R Kalden, J S Smolen, C E Antoni, J W J Bijlsma, G R Burmester, B Cronstein, E C Keystone, A Kavanaugh, and L Klareskog
Ann Rheum Dis 2002; 61 (Supplement 2
): 2. doi:10.1136/ard.61.suppl_2.ii2
[Extract]
[Full text]
[PDF]
[Request Permissions]
Subversion of the innate immune response by micro-organisms
B Fernie-King, D J Seilly, A Davies, and P J Lachmann
Ann Rheum Dis 2002; 61 (Supplement 2
): 8. doi:10.1136/ard.61.suppl_2.ii8
[Extract]
[Full text]
[PDF]
[Request Permissions]
Is NF- B a useful therapeutic target in rheumatoid arthritis?
M Feldmann, E Andreakos, C Smith, J Bondeson, S Yoshimura, S Kiriakidis, C Monaco, C Gasparini, S Sacre, A Lundberg, E Paleolog, N J Horwood, F M Brennan, and B M J Foxwell
Ann Rheum Dis 2002; 61 (Supplement 2
): 13. doi:10.1136/ard.61.suppl_2.ii13
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis
R Boismenu, Y Chen, K Chou, A El-Sheikh, and R Buelow
Ann Rheum Dis 2002; 61 (Supplement 2
): 19. doi:10.1136/ard.61.suppl_2.ii19
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Balancing the immune system: Th1 and Th2
W van Eden, R van der Zee, P van Kooten, S E Berlo, P M Cobelens, A Kavelaars, C J Heijnen, B Prakken, S Roord, and S Albani
Ann Rheum Dis 2002; 61 (Supplement 2
): 25. doi:10.1136/ard.61.suppl_2.ii25
[Extract]
[Full text]
[PDF]
[Request Permissions]
Mesenchymal stem cells. A potential source for skeletal repair
W E Fibbe
Ann Rheum Dis 2002; 61 (Supplement 2
): 29. doi:10.1136/ard.61.suppl_2.ii29
[Extract]
[Full text]
[PDF]
[Request Permissions]
Role of RANKL and RANK in bone loss and arthritis
D Holstead Jones, Y-Y Kong, and J M Penninger
Ann Rheum Dis 2002; 61 (Supplement 2
): 32. doi:10.1136/ard.61.suppl_2.ii32
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Functions of AP1 (Fos/Jun) in bone development
E F Wagner
Ann Rheum Dis 2002; 61 (Supplement 2
): 40. doi:10.1136/ard.61.suppl_2.ii40
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Treatments no longer in development for rheumatoid arthritis
E Keystone
Ann Rheum Dis 2002; 61 (Supplement 2
): 43. doi:10.1136/ard.61.suppl_2.ii43
[Extract]
[Full text]
[PDF]
[Request Permissions]
Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis
J E Salmon, G Girardi, and V M Holers
Ann Rheum Dis 2002; 61 (Supplement 2
): 46. doi:10.1136/ard.61.suppl_2.ii46
[Extract]
[Full text]
[PDF]
[Request Permissions]
Behçets disease: a new target for anti-tumour necrosis factor treatment
P P Sfikakis
Ann Rheum Dis 2002; 61 (Supplement 2
): 51. doi:10.1136/ard.61.suppl_2.ii51
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Protection against tuberculosis: cytokines, T cells, and macrophages
S H E Kaufmann
Ann Rheum Dis 2002; 61 (Supplement 2
): 54. doi:10.1136/ard.61.suppl_2.ii54
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Epidemiology, diagnostic possibilities, and treatment of tuberculosis
R Kurth and W H Haas
Ann Rheum Dis 2002; 61 (Supplement 2
): 59. doi:10.1136/ard.61.suppl_2.ii59
[Extract]
[Full text]
[PDF]
[Request Permissions]
Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents
D E Furst, J Cush, S Kaufmann, J Siegel, and R Kurth
Ann Rheum Dis 2002; 61 (Supplement 2
): 62. doi:10.1136/ard.61.suppl_2.ii62
[Extract]
[Full text]
[PDF]
[Request Permissions]
Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis
V Strand, R Landéwé, and D van der Heijde
Ann Rheum Dis 2002; 61 (Supplement 2
): 64. doi:10.1136/ard.61.suppl_2.ii64
[Extract]
[Full text]
[Web only figure]
[PDF]
[Request Permissions]
Infliximab treatment for rheumatic disease: clinical and radiological efficacy
E W St Clair
Ann Rheum Dis 2002; 61 (Supplement 2
): 67. doi:10.1136/ard.61.suppl_2.ii67
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Adalimumab (a fully human anti-tumour necrosis factor monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials
R Rau
Ann Rheum Dis 2002; 61 (Supplement 2
): 70. doi:10.1136/ard.61.suppl_2.ii70
[Extract]
[Full text]
[PDF]
[Request Permissions]
Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis
B Bresnihan
Ann Rheum Dis 2002; 61 (Supplement 2
): 74. doi:10.1136/ard.61.suppl_2.ii74
[Extract]
[Full text]
[PDF]
[Request Permissions]
Type II collagen degradation and its regulation in articular cartilage in osteoarthritis
A R Poole, M Kobayashi, T Yasuda, S Laverty, F Mwale, T Kojima, T Sakai, C Wahl, S El-Maadawy, G Webb, E Tchetina, and W Wu
Ann Rheum Dis 2002; 61 (Supplement 2
): 78. doi:10.1136/ard.61.suppl_2.ii78
[Extract]
[Full text]
[PDF]
[Request Permissions]
Tumour necrosis factor superfamily cytokines and the pathogenesis of inflammatory osteolysis
J Lam, Y Abu-Amer, C A Nelson, D H Fremont, F P Ross, and S L Teitelbaum
Ann Rheum Dis 2002; 61 (Supplement 2
): 82. doi:10.1136/ard.61.suppl_2.ii82
[Extract]
[Full text]
[PDF]
[Request Permissions]
Bone destruction in arthritis
E M Gravallese
Ann Rheum Dis 2002; 61 (Supplement 2
): 84. doi:10.1136/ard.61.suppl_2.ii84
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Cartilage destruction in rheumatoid arthritis
S Gay, S Kuchen, R E Gay, and M Neidhart
Ann Rheum Dis 2002; 61 (Supplement 2
): 87. doi:10.1136/ard.61.suppl_2.ii87
[Extract]
[Full text]
[PDF]
[Request Permissions]
Pharmacovigilance: towards a better understanding of the benefit to risk ratio
L S Simon
Ann Rheum Dis 2002; 61 (Supplement 2
): 88. doi:10.1136/ard.61.suppl_2.ii88
[Extract]
[Full text]
[PDF]
[Request Permissions]
Weight and consequences of post-marketing (-approval) experience
G Kreutz
Ann Rheum Dis 2002; 61 (Supplement 2
): 90. doi:10.1136/ard.61.suppl_2.ii90
[Extract]
[Full text]
[PDF]
[Request Permissions]
The National Institute for Clinical Excellence (NICE)
A-T Rodgers
Ann Rheum Dis 2002; 61 (Supplement 2
): 92. doi:10.1136/ard.61.suppl_2.ii92
[Extract]
[Full text]
[PDF]
[Request Permissions]
Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases
R L Wilder
Ann Rheum Dis 2002; 61 (Supplement 2
): 96. doi:10.1136/ard.61.suppl_2.ii96
[Abstract]
[Full text]
[PDF]
[Request Permissions]
Role of interleukin 15 and interleukin 18 in inflammatory response
F Y Liew and I B McInnes
Ann Rheum Dis 2002; 61 (Supplement 2
): 100. doi:10.1136/ard.61.suppl_2.ii100
[Abstract]
[Full text]
[PDF]
[Request Permissions]